Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone oral suspension in Chinese patients with CDKL5 deficiency disorder
ChiCTR2500097498Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Feb 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ganaxolone in CDKL5 deficiency disorder (CDD), sponsored by Children's Hospital of Fudan University. Primary endpoints: Safety analysis, Efficacy analysis (seizure frequency change) and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ganaxolone
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on ChiCTR2500097498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097498.